INTRODUCTION

Neuroblastoma is the most common extracranial solid tumour of childhood and accounts for 15% of cancer-related deaths. Despite recent advances in cancer treatment, aggressive neuroblastomas remain refractory to current therapy; the overall 5-year survival rate for patients with advanced-stage neuroblastoma is 30%-40%.

Amplification of MYCN oncogene is observed in approximately 20% of neuroblastomas and 45% of high-risk cases. MYCN amplification is strongly associated with poor outcome and has been considered as the most important prognostic factor, which strongly correlated with advanced-stage disease and treatment failure. The deregulation of MYCN oncogene that regulates the expression of genes involved in several processes, including cell cycle, proliferation, apoptosis, and survival.
differentiation\textsuperscript{10,11} and apoptosis,\textsuperscript{6,8,10} is sufficient to drive the transformation of neural crest progenitor cells into neuroblastoma.

Tumour necrosis factor (TNF)–related apoptosis-inducing ligand (TRAIL), also known as the Apo-2 ligand, is a member of TNF ligand superfamily that selectively induces apoptosis in a wide variety of transformed cell lines from diverse tissue types.\textsuperscript{12} TRAIL may induce apoptosis through its interaction with two of four membrane-bound receptors, namely death receptor 4 (DR4; TRAIL-R1) and DR5 (TRAIL-R2). These receptors bear a protein-protein interaction motif termed as the "death domain (DD)".\textsuperscript{13,14} The other two receptors, decoy receptor 1 (DcR1; TRAIL-R3) and DcR2 (TRAIL-R4), either lack the cytoplasmic or truncated DD. TRAIL induces receptor trimerization and conformational change in the intracellular DD, resulting in the recruitment of Fas-associated DD.\textsuperscript{15} This signals death through the formation of a death-inducing signal complex, which rapidly activates caspase-8. Caspase-8 mediates apoptosis either through the direct activation of the downstream effector caspasers or by the cleavage of pro-apoptotic molecules such as B-cell lymphoma 2 (Bcl-2) homolog, Bid.\textsuperscript{16,17}

Studies have shown that anti-cancer drugs such as bortezomib,\textsuperscript{18,19} etoposide\textsuperscript{20} and doxorubicin\textsuperscript{21} sensitized cancer cells to TRAIL-mediated death through the upregulation of DR expression. In particular, the upregulation of DRs by cisplatin affected TRAIL-induced apoptosis in many cancer types, such as squamous carcinoma,\textsuperscript{22} hepatocellular carcinoma\textsuperscript{23} and colon cancer.\textsuperscript{24} The mechanism underlying the upregulation of TRAIL receptors is variable. The activation or inhibition of nuclear factor kappa B (NF-κB)\textsuperscript{20,25} and/or extracellular signal–regulated kinase (ERK) 1/2\textsuperscript{26,27} may upregulate both DR4 and DR5, while p53 may mediate the upregulation of DR5 at transcriptional levels.\textsuperscript{28} In addition, chemotherapeutic agents may mediate the changes in the rate of receptor turnover at cell surface.\textsuperscript{29,30}

In this study, we investigated whether cisplatin treatment triggers TRAIL-mediated cytotoxicity in TRAIL-resistant IMR-32 neuroblastoma cells which exhibit amplification of MYCN oncogene and lack caspase-8 expression. Our data, for the first time, show that TRAIL susceptibility correlated with the expression levels of N-myc and caspase-8 in human neuroblastoma IMR-32 cells. The combination therapy of cisplatin and TRAIL is a promising strategy for treating neuroblastoma that is controlled by the expression of N-myc and caspase-8, and its use may provide important information for the development of additional potential therapeutic strategies to fight neuroblastoma.

2 | MATERIALS AND METHODS

2.1 | Reagents

Cisplatin was purchased from Dong-A Pharm (Seoul, Korea) and NF-κB activation inhibitor from Calbiochem (Darmstadt, Germany). Human recombinant TRAIL, Alamar Blue® and trypan blue were purchased from Life Technologies (Rockville, MD); interferon (IFN)-γ, human recombinant DR5/Fc chimera (DR5:Fc) protein and phycoerythrin (PE)-conjugated antibodies for DR4, DR5, DcR1 and DcR2, from R&D Systems (Minneapolis, MN); antibodies for N-myc, Bid, p27\textsuperscript{kip1}, p21\textsuperscript{Cip1/Waf1}, caspase-3 and caspase-9, from Cell Signaling Technology (Danvers, MA); and antibodies for caspase-8, Bcl-2, Bax, poly(ADP-ribose) polymerase (PARP) and β-actin, scrambled shRNA (Cat. No: sc-108080) as well as N-myc shRNA (Cat. No: sc-36003-V) lentiviral particles, and polybrene, from Santa Cruz Biotechnology (Santa Cruz, CA).

Hoechst 33258 dye and puromycin were purchased from Sigma-Aldrich (St. Louis, MO), and tetramethylrhodamine ethyl ester perchlorate (TMRE) was purchased from Thermo Fisher Scientific (Waltham, MA).

2.2 | Cell viability: Alamar Blue assay

Human malignant neuroblastoma cell lines IMR-32 and SK-N-BE, and neuroepithelioima cell line SK-N-MC were purchased from the American Type Culture Collection (ATCC; Manassas, VA). Details of the cell culture are described in Supporting information Methods. Cells (2 × 10\textsuperscript{4} cells/well) were seeded in a 96-well plate (Nalgene Nunc, Naperville, IL), in 100 μL of Dulbecco’s modified Eagle’s medium (DMEM; Biowest, Nuaillé, France) containing 1% heat-inactivated foetal bovine serum (FBS; Biowest) in the absence of phenol red, and treated for 24-96 hours with either IFN-γ, DR5:Fc, NF-κB activation inhibitor, cisplatin or TRAIL, separately and in different combinations. Then, 3 hours before the end of the incubation, cells were treated with 11 μL of 1× Alamar Blue®, and their absorbance was measured at 570 and 600 nm wavelength with an enzyme-linked immunosorbent assay (ELISA) reader (Molecular Devices, Sunnyvale, CA).

2.3 | Flow cytometry

For the measurement of TRAIL receptor expression, 10\textsuperscript{6} cells were suspended in 0.1 mL of phosphate-buffered saline (PBS; Biowest) and incubated with PE-conjugated antibodies for 45 minutes at 4°C. PE-conjugated human IgG (R&D Systems) was used as isotype control at concentrations similar to that of the specific antibodies. The fluorescence intensity of the samples was evaluated with fluorescence-activated cell sorting (FACScalibur; BD Bioscience, San Jose, CA), and data were analysed using CELLQUEST software (BD Bioscience).

2.4 | Measurement of human NF-κB (p50/ p65) activity

The DNA-binding activity of NF-κB in cells was quantified by ELISA using NF-κB p50 and p65 transcription factor assay kit (Cayman, Ann Arbor, MI) according to the manufacturer’s instructions. Details of the measurement of NF-κB activity are described in supplementary methods.

2.5 | Immunoblotting

Cells were washed with cold PBS and lysed in cold radioimmuno-precipitation assay (RIPA) lysis buffer (Thermo Fisher Scientific) with a protease inhibitor cocktail (Thermo Fisher Scientific). Cell lysates were centrifuged at 3000 g for 15 minutes at 4°C. The supernatant was harvested and the protein concentration analysed using the BCA protein assay kit. For electrophoresis, 50 μg of protein was...
dissolved in the reduced sample buffer (Thermo Fisher Scientific) and separated on a NuPAGE 4%-12% Bis-Tris gel (Novex, Carlsbad, CA). Separated proteins were transferred onto polyvinylidene difluoride membranes (GE Healthcare, Buckinghamshire, UK). Blots were blocked for 1 hour in Tris-buffered saline (TBS; Biosesang, Korea) containing 2% bovine serum albumin (Life Technologies–Gibco), washed thrice with 0.3% TBST (TBS containing 0.3% Tween 20 [Sigma-Aldrich]) and incubated at 4°C overnight with primary antibodies (all antibodies, 1:1000 dilution) in 0.1% TBST. Blots were then washed thrice with 0.3% TBST and incubated for 1 hour with horseradish peroxidase–conjugated secondary antibodies (1:3000 dilution, Cell Signaling Technology) in 0.3% TBST. After washing thrice with 0.3% TBST, protein bands were visualized with an enhanced chemiluminescence detection system (GE Healthcare).

2.6 | Luminex assay

Caspase-3 activation and PARP cleavage were assessed using 3-Plex Apoptosis Signaling Kit (Merck Millipore, St. Charles, MO) according to the manufacturer’s instructions. Details of the Luminex assay are described in Supplementary methods.

2.7 | Nuclear staining and phase-contrast microscopy

Cells were treated with IFN-γ, cisplatin and TRAIL, either separately or in different combinations. After treatment, cells were incubated with Hoechst 33258 at a final concentration of 5 μg/mL in HEPES buffer (Life Technologies–Gibco) for 20 minutes at 37°C in a 5% CO₂ incubator. Cells were then washed with PBS and resuspended in PBS and were examined with a Nikon Eclipse TE2000-U inverted fluorescence microscope equipped with a Nikon LH-M100C-1 camera (Nikon Corporation Instruments Company, Japan).

2.8 | Establishment of N-myc–downregulated IMR-32 cells

For the transduction of IMR-32 cells with N-myc–downregulating lentiviral particles, cells were pretreated with 5 μg/mL polybrene, prepared in DMEM containing 10% FBS and incubated with the lentivirus at a multiplicity of infection (MOI) of 5. After incubating for 24 hours at 37°C with 5% CO₂, cells were washed twice with PBS and fresh medium was added. Infected cells were selected after 10 days of incubation in the medium containing 5 μg/mL puromycin, after 2 weeks of transduction. The protein level of N-myc was confirmed by Western blot analysis.

2.9 | Phase-contrast microscopy and cell counting

Viable cells were incubated at 37°C with 5% CO₂, and the medium was changed every 3-4 days. Cells were observed on days 3, 7 and 14, using an inverted microscope (Olympus CK40, Melville, NY). Collected cells were resuspended in PBS and stained with trypan blue. The total number of viable cells was determined using a haemocytometer (Marienfeld, Germany).

2.10 | Measurement of mitochondrial membrane potential: TMRE staining

The mitochondrial membrane potential (MMP, Ψm) was measured with the fluorescent dye TMRE. Cells were incubated with TMRE at a final concentration of 50 nmol/L in HEPES buffer for 20 minutes at 37°C in a 5% CO₂ incubator. Cells were then washed with PBS and examined using a Nikon Eclipse TE2000-U inverted fluorescence microscope equipped with a Nikon LH-M100C-1 camera.

2.11 | Statistical analysis

All data were expressed as mean ± standard deviation (SD). Student’s t test was used for statistical comparison between groups. A value of P < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Cisplatin increased DR5 expression in IMR-32 cells via downregulation of NF-κB activity

To examine whether cisplatin induces cell death in neuroblastoma IMR-32 and SK-N-BE cell lines, cells were treated with 100-1000 ng/mL cisplatin for the indicated time. Although low concentrations of cisplatin showed limited cytotoxic effect, a gradual increase in the death of neuroblastoma IMR-32 (Figure 1A) and SK-N-BE cells (Figure S1A) was observed with an increase in cisplatin concentration. To elucidate the effect of cisplatin on the expression of TRAIL receptors, we examined the expression levels of TRAIL receptors in IMR-32 and SK-N-BE cells after cisplatin treatment by flow cytometry. As shown in Figures 1B and C, only DR5 was expressed in IMR-32 cells, and cisplatin induced the expression of DR5 in these cells. Unlike IMR-32 cells, TRAIL receptors were detected at low levels in SK-N-BE cells, and cisplatin treatment increased the expression of all TRAIL receptors (Figures S1B and C). Moreover, cisplatin treatment significantly decreased NF-κB activity in IMR-32 cells in a dose-dependent manner (Figure 1D). Consistent with these results, NF-κB activation inhibitor decreased NF-κB activities in IMR-32 cells (Figure 1E), accompanied by an increase in DR5 expression (Figure 1F). We also established NF-κB–downregulated IMR-32 cells using shRNA-targeting NF-κB p65 and observed that these cells showed increased expression of DR5, which was unaffected by cisplatin treatment (Figure S2). These results indicated that cisplatin treatment increased DR5 expression in IMR-32 cells, via downregulation of NF-κB activity.

3.2 | Cisplatin failed to trigger TRAIL cytotoxicity in TRAIL-resistant IMR-32 cells

We measured the susceptibility of human neuroblastoma IMR-32 and SK-N-BE cells to TRAIL with Alamar Blue assay. TRAIL
treatment had no cytotoxic effect on both cells (Figures 2A and S3A). As described above, cisplatin treatment increased TRAIL receptors, particularly DR5, only in IMR-32 cells. To elucidate the effect of increased TRAIL receptors on cytotoxicity, we analysed the expression of TRAIL receptors (DR4, DR5, DcR1 and DcR2) in IMR-32 cells by flow cytometry using PE-conjugated antibodies. Positive cells were plotted against the appropriate IgG isotype controls (shaded histogram). Data were obtained at 24 h after treatment with vehicle (unshaded grey line) or 750 ng/mL cisplatin (unshaded black line). Changes in the expression of TRAIL receptors in response to cisplatin are shown as (B) histogram and (C) bar graph. D, Cells treated with the indicated concentrations of cisplatin or E, NF-κB inhibitor for 12 h. Nuclear extracts were prepared from these cells, and the DNA-binding activity of NF-κB was quantified by ELISA. Data are expressed as a fold change over vehicle-treated control cells (mean ± SD) from two independent experiments. F, Changes in the expression of TRAIL receptors in response to treatment with NF-κB inhibitor for 24 h. Data are expressed as a percentage of IgG isotype controls (mean ± SD) from three independent experiments. Cis, cisplatin

3.3 | Interferon-γ restored caspase-8 expression in IMR-32 cells but failed to induce TRAIL cytotoxicity

In contrast to SK-N-MC cells used as a positive control, IMR-32 and SK-N-BE cells were negative for caspase-8 expression (Figure 3A), which was unaltered by cisplatin and/or TRAIL treatment for 24 hours (Figure 3B). To restore the expression of caspase-8 in IMR-32 cells, we treated these cells with a demethylating agent, IFN-γ or 5-azacytidine (5-AzaC), for 24 hours and found that the caspase-8 expression was significantly restored (Figures 3C and 4A). 5-AzaC treatment slightly induced cell death (Figure S4B), but pretreatment with 5-AzaC and/or IFN-γ failed to trigger TRAIL cytotoxicity in IMR-32 cells (Figure S4B and C). Although caspase-8 expression was restored in IMR-32 cells exposed to IFN-γ, treatment of these cells with cisplatin failed to trigger TRAIL-induced cell death (Figure 3D and E). Moreover, treatment with NF-κB activation inhibitor failed to induce TRAIL cytotoxicity in IFN-γ-treated IMR-32 cells (Figure 3F). These
results indicate that the restoration of caspase-8 expression in IMR-32 cells by IFN-γ treatment failed to induce TRAIL cytotoxicity, although cisplatin increased DR5 expression via downregulation of NF-κB activity.

3.4 | Protein kinase B (Akt) or ERK signalling pathway had no role in the susceptibility of IMR-32 cells to TRAIL

To identify the factors that confer IMR-32 cells resistance to TRAIL, we examined the expression levels of several molecules related to cell death. As shown in Figure S5, phosphorylated (p-) Akt (Thr^308), p-Akt (Ser^473) and p-ERK1/2 were increased by cisplatin treatment, while the expression levels of other molecules such as cellular FLICE-like inhibitor protein (c-FLIP) long (c-FLIP_L), c-FLIP short (c-FLIP_S), heat-shock protein (HSP) 70, survivin and Mcl-1 rarely changed. To inhibit Akt or ERK signalling pathway in these cells, we pretreated them with the chemical inhibitor LY294002 or U0126, respectively, and found that neither LY294002 nor U0126 had any significant effect on cell death induced by cisplatin and/or TRAIL treatment (Figure S6A and B). We obtained similar results in caspase-8-positive IMR-32 cells treated with IFN-γ (Figure S6C and D), indicating that Akt or ERK signalling pathway had no role in the susceptibility of TRAIL-resistant IMR-32 cells to TRAIL.
3.5 | Inhibition of N-myc expression affected the molecular and cellular characteristics in IMR-32 cells

Compared to the negative control SK-N-MC cells, IMR-32 and SK-N-BE cells showed increased expression of N-myc (Figure 4A), which was unaltered following cisplatin and/or TRAIL treatment for 24 hours (Figure 4B). In addition, Bcl-2 family proteins such as Bcl-2, Bid and Bax were highly expressed in IMR-32 cells (Figure 4A), and their expression levels were unaffected by cisplatin and/or TRAIL treatment (Figure 4B). Next, we established N-myc–downregulated IMR-32 cells using shRNA lentiviral particles targeting N-myc and observed an effective decrease in N-myc expression in them (Figure 4C). The downregulation of N-myc expression affected the molecular and cellular characteristics of IMR-32 cells. Transduction with scrambled shRNA had marginal effect on the morphology of IMR-32 cells, while N-myc-downregulated IMR-32 cells were not colonized and showed some morphological changes such as flat cell bodies (Figure 4D). Moreover, N-myc–downregulated IMR-32 cells showed an increase in the expression of p27Kip1 (Figure 4E), leading to decreased proliferation in culture (Figure 4F). In addition, N-myc–downregulated IMR-32 cells showed a decrease in Bcl-2 expression (Figure 4E), which could induce a mild collapse of MMP in these cells (Figure 4G). Although N-myc downregulation failed to restore caspase-8 expression (Figure 4H), the activation of caspase-9 and caspase-3, and cleavage of PARP were slightly increased in IMR-32 cells (Figure 4I). These results suggest that the inhibition of N-myc expression can change the characteristics of IMR-32 cells and increase their susceptibility to cell death.

3.6 | Inhibition of N-myc expression sensitized IMR-32 cells expressing caspase-8 to TRAIL

Next, we examined the effect of N-myc inhibition on TRAIL susceptibility in IMR-32 cells. The treatment of myc–downregulated IMR-32 cells with IFN-γ to restore caspase-8 expression resulted in about 20% cell death (Figures 5A and S7), and treatment with IFN-γ and TRAIL further increased the cell death to about 40% (Figure 5B). In addition, N-myc–downregulated IMR-32 cells pretreated with IFN-γ and subjected to cisplatin and TRAIL co-treatment showed a dramatic increase in apoptotic cell death (almost 90%), which was accompanied by nuclear condensation and fragmentation, compared to IFN-γ–untreated cells (Figure 5C and D). Moreover, the activation
of caspase-9 and caspase-3 and cleavage of PARP significantly increased in these cells (Figure 5E). An additional pretreatment of these cells with DR5:Fc chimera protein effectively abrogated the increased cell death (Figure 5B and C), indicating that the restored TRAIL cytotoxicity induced apoptosis-mediated cell death. TRAIL cytotoxicity was also observed in IMR-32 cells that are controlled by N-my c and caspase-8 expression, when pretreated with NF-κB inhibitor (Figure 5F). In addition, the activation of caspase-9 and caspase-3 and cleavage of PARP significantly increased in these cells (Figure 5G). These results indicate that the inhibition of N-myc expression sensitized IMR-32 cell expressing caspase-8 to TRAIL, and this effect was dramatically enhanced in the presence of cisplatin, via increased expression of DR5 through the downregulation of NF-κB activity.

**DISCUSSION**

Tumour necrosis factor–related apoptosis-inducing ligand is widely used for cancer therapy and effectively kills several transformed cells but not normal cells. Although TRAIL may serve as a promising cancer therapeutic agent, many cancer cells exhibit partial or complete resistance to TRAIL. This resistance may be attributed to the deregulated expression of the TRAIL receptors or intracellular components which act downstream of the receptors. Previous studies have shown that the conventional chemotherapeutic agents, irradiation and histone deacetylase inhibitors enhance the cytotoxicity of TRAIL via upregulation of TRAIL receptors. The upregulation in the expression of DRs by chemotherapeutic agents is dependent on the activity of NF-κB or p53, which
transcriptionally regulates the expression of DRs by binding to the promoter sites. In particular, the upregulation in DR expression by cisplatin results in an increase in TRAIL-induced cell death in various cancer cells. In this study, cisplatin increased the expression of DR5 in neuroblastoma IMR-32 cells via downregulation of NF-κB activity, while increased DR5 levels failed to trigger TRAIL cytotoxicity in TRAIL-resistant IMR-32 cells, which showed amplified MYCN expression and lacked caspase-8 expression.

Caspase-8 is an essential mediator for the initiation of DR-induced apoptosis and frequently absent in cancers such as neuroblastoma, medulloblastoma, small cell lung cancer and melanoma. The loss of caspase-8 expression correlates with low sensitivity to TRAIL cytotoxicity. Cancer cells expressing caspase-8 are sensitive to TRAIL cytotoxicity, while cells lacking caspase-8 are TRAIL-resistant. Moreover, cells lacking caspase-8 are sensitized to TRAIL cytotoxicity upon restoration of caspase-8 expression in these cells by 5-AzaC or IFN-γ. The loss of caspase-8 expression is the result of gene silencing by aberrant methylation and may be restored by treatment with demethylation agents such as AzaC. However, the clinical use of demethylating agents has been limited, owing to their toxic side effects. IMR-32 cells used in this study were negative for caspase-8 expression, and treatment of these cells with IFN-γ restored their caspase-8 expression. IFN-γ restores caspase-8 expression through its transcriptional activation, which involves signal transducer and activator of transcription 1 (STAT1) or interferon regulatory factor 1 (IRF1) pathway. Recent reports showed that IFN-γ may increase caspase-8 levels and thereby sensitize tumour cells to apoptotic stimuli. In this study, however, IFN-γ-mediated restoration of caspase-8 had no effect on TRAIL-induced cell death, suggestive of the involvement of other factors in TRAIL resistance in IMR-32 cells.

The neuroblastoma cell line IMR-32 shows amplification of MYCN oncogene and contains more than 25 copies of MYCN oncogene per cell. The amplification of MYCN oncogene is one of the most powerful prognostic factors in neuroblastoma, and its positive effects on tumorigenesis are well known; thus, strategies for targeting N-myc may serve as a promising approach for neuroblastoma therapies. In this study, we used retrovirus-mediated delivery of N-myc shRNA to downregulate N-myc protein expression in IMR-32 cells. TRAIL treatment in these N-myc-negative cells slightly induced apoptotic cell death,
and TRIAL cytotoxicity was increased upon pretreatment of these cells with IFN-γ. TRIAL cytotoxicity was abrogated by an additional pretreatment with DR5:Fc chimera protein, indicating that the inhibition of N-myc expression triggered TRIAL cytotoxicity in IMR-32 cells expressing caspase-8.

N-myc protein is generally known to modulate the function of the extrinsic death-inducing pathway as a molecule downstream of TRAIL receptors as well as the intrinsic apoptosis pathway, which plays a role in maintaining the integrity of the mitochondria via Bcl-2 family proteins. Several reports suggest that Bcl-2 expression correlates with the expression levels of N-myc protein, and together, these may promote the survival of lymphoma and neuroblastoma. How N-myc downregulation may lead to decreased Bcl-2 expression in cancer cells is questionable. Here, we showed that N-myc protein inhibition in IMR-32 cells decreased the expression of Bcl-2, which decreases the stability of MMP, and regulated the activation of caspases to induce apoptosis. Bcl-2 protein inhibits the release of cytochrome c from mitochondria to the cytosol and regulates the activation of caspases for apoptosis induction. In addition, many reports showed that the inhibition of Bcl-2 expression by chemotherapeutic agents increased the sensitivity of cancer cells to TRAIL.

Our results demonstrate for the first time that the inhibition of N-myc expression sensitizes IMR-32 cells expressing caspase-8 to TRIAL. The treatment of TRAIL-resistant IMR-32 cells with cisplatin resulted in an increased DR5 expression but failed to trigger TRAIL sensitivity. Furthermore, the downregulation of N-myc expression and restoration of caspase-8 expression in TRAIL-resistant IMR-32 cells may activate TRAIL signalling, thereby inducing apoptotic cell death. Cisplatin pretreatment dramatically enhanced TRAIL cytotoxicity via increased DR5 expression in these cells. In conclusion, our data suggest that the combination therapy of cisplatin and TRAIL is a promising strategy for treating neuroblastoma that is controlled by the expression of N-myc and caspase-8, and its use may provide important information for the development of additional potential therapeutic strategies to fight neuroblastoma.

ACKNOWLEDGEMENTS
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2014R1A1A1008388) and by the Ministry of Education (2017R1D1A1B03027984).

DISCLOSURE
The authors declare that they have no competing interests.

AUTHOR CONTRIBUTIONS
This study was designed and supervised by MWL and KHY. Experiments were conducted by DSK, HRK and HJP. Data analysis was conducted by MWL, DSK, JWL, KWS, HHK and KHY. Funding was obtained by MWL and KHY. The manuscript was written by MWL and KHY. All authors have read and approved the final manuscript.

ORCID
Keon Hee Yoo https://orcid.org/0000-0002-5980-7912

REFERENCES
1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55(1):97-120.
2. Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008-3017.
3. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-1124.
4. Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res. 2013;19(21):5814-5821.
5. Iehara T, Hosoi H, Akazawa K, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer. 2006;94(10):1510-1515.
6. Creevey L, Ryan J, Harvey H, et al. MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer. 2013;12:23.
7. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyanine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene. 2005;24(36):5606-5618.
8. He J, Gu L, Zhang H, Zhou M. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma. Cell Cycle. 2011;10(17):2994-3002.
9. Huang R, Cheung NK, Vider J, et al. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas. FASEB J. 2011;25(12):4138-4149.
10. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 2006;351(1):192-197.
11. Lovén J, Zinin W, Zhao Q, et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. Proc Natl Acad Sci USA. 2010;107(4):1553-1558.
12. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis inducing ligand and TRAIL receptor pathway. Oncogene. 2008;27(48):6207-6215.
13. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007;39(7-8):1462-1475.
14. Wajant H. Death receptors. Essays Biochem. 2003;39:53-71.
15. Berg D, Lehne M, Müller N, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007;14(12):2021-2034.
16. Kim WS, Lee KS, Kim JH, et al. The caspase-8/Bid/cytochrome c axis links signals from death receptors to mitochondrial reactive oxygen species production. Free Radic Biol Med. 2017;112:567-577.
17. Wu H, Che X, Wheng Q, et al. Caspases: a molecular switch node in the crosstalk between autophagy and apoptosis. Int J Biol Sci. 2014;10(9):1072-1083.
18. Bychkov ML, Gasparian ME, Dolgikh DA, Kirpichnikov MP. Combination of TRAIL with bortezomib shifted apoptotic signaling from DR4 to DR5 death receptor by selective internalization and degradation of DR4. PLoS ONE. 2014;9(10):e109756.

19. Chen KF, Yeh PY, Hsu C, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2009;284(17):11121-11133.

20. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20(1):205-212.

21. Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer. 2010;9:87.

22. Kondo K, Yamasaki S, Sugie T, et al. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma. Int J Cancer. 2006;118(1):230-242.

23. Shin EC, Seong YR, Kim CH, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med. 2002;34(2):114-122.

24. van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer. 2003;89(2):363-373.

25. Shetty S, Gladden JB, Henson ES, et al. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis. 2002;7(5):413-420.

26. Gupta SC, Reuter S, Phromnoi K, et al. Nimbolide sensitizes human neuroblastoma cells to TRAIL-mediated apoptosis by up-regulation of death receptor 5 via ROS. Food Chem Toxicol. 2017;106(Pt A):514-521.

27. Kalan S, Amat R, Schachter MM, et al. Activation of the p53 transcriptional program sensitizes cancer cells to Cdk7 inhibitors. Cell Rep. 2017;21(2):467-481.

28. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intrinsic p53 binding site. Cancer Res. 2004;64(15):5078-5083.

29. Yoshida T, Maeda A, Tani N, Sakai T. Promoter structure and transcription initiation sites of the human death receptor 5/TRAIL-R2 gene. FEBS Lett. 2001;507(3):381-385.

30. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001;20(41):5865-5877.

31. Kavuri SM, Geserick P, Berg D, et al. Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex. J Biol Chem. 2011;286(19):16631-16646.

32. Fulda S, Debatin KM, 5-Aza-2′-deoxycytidine and IFN-gamma cooperate to sensitize for TRAIL-induced apoptosis by upregulating caspase-8. Oncogene. 2006;25(37):5125-5133.

33. Hopkins-Donaldson S, Bodmer JL, Bourk W, Brogna C, Tschopp J, Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2000;60(16):4315-4319.

34. Meister N, Shalaby T, von Bueren AO, et al. Interferon-gamma mediated up-regulation of caspase-8 sensitizes medulloblastoma cells to radio- and chemotherapy. Eur J Cancer. 2007;43(12):1833-1841.

35. Kaminskiy VO, Surova O, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis. 2011;32(10):1450-1458.

36. Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment. Apoptosis. 2008;13(6):756-770.

37. Hwang JS, Lee YY, Lee DH, Kwon KH. DATS sensitizes glioma cells to TRAIL-mediated apoptosis by up-regulation of death receptor 5 via ROS. Food Chem Toxicol. 2017;106(PT A):514-521.

38. Ricci MS, Kim SH, Ogi K, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007;12(1):66-80.
55. Noujaim D, van Golen CM, van Golen KL, Grauman A, Feldman EL. N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells. Oncogene. 2002;21(29):4549-4557.

56. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol. 1993;143(6):1543-1550.

57. Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21(15):5063-5070.

58. Jasty R, van Golen C, Lin HJ, et al. Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia. 2001;3(4):304-313.

59. Kvansakul M, Hinds MG. The Bcl-2 family: structures, interactions and targets for drug discovery. Apoptosis. 2015;20(2):136-150.

60. Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kögel D. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol. 2008;86(3):265-272.

61. Siegelin MD, Gaiser T, Habel A, Siegelin Y. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett. 2009;283(2):230-238.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Lee MW, Kim DS, Kim HR, et al. Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL. Cell Prolif. 2019;52:e12577. https://doi.org/10.1111/cpr.12577